Delivery Order SPE2D021D0003-SPE2D022F0106
- Not listed
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Sagent Pharmaceuticals, Inc. The contract has a ceiling value of $58,926.51 and is a delivery order with a firm fixed price pricing type. The contract does not have a set-aside designation, indicating Sagent Pharmaceuticals competed on an unrestricted basis. The contract is for the delivery of various injectable pharmaceutical products, such as antibiotics, critical care medications, and...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Sagent Pharmaceuticals, Inc., a specialty pharmaceutical manufacturer. The $117,701.97 firm fixed price contract is for the supply of various injectable pharmaceutical products, including antibiotics and anesthesia medications, to support military healthcare programs. The contract has an ultimate completion date of April 3, 2024. Sagent Pharmaceuticals is an experienced federal contractor,...
- This is a $3,083,212.80 firm fixed-price delivery order contract awarded by the Centers for Disease Control and Prevention (CDC) to Sagent Pharmaceuticals, Inc., a specialty pharmaceutical manufacturer. The contract, which does not have a set-aside designation, is for the supply of injectable pharmaceutical products such as antibiotics, critical care medications, and anesthesia drugs to support military healthcare programs and other federal medical needs. Sagent Pharmaceuticals is a prime...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Sagent Pharmaceuticals, Inc., a specialty and generic pharmaceutical manufacturer. The $121,974.52 firm fixed price order is for the delivery of various injectable pharmaceutical products, including antibiotics and anesthesia medications, to support military healthcare programs. The order has an April 2025 completion date. This delivery order is issued under a larger $29.6 million indefinite...
- This is a firm fixed price delivery order awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh to Sagent Pharmaceuticals, Inc., a specialty pharmaceutical manufacturer. The $13,146,933.60 indefinite-delivery, indefinite-quantity (IDIQ) contract is for the delivery of injectable pharmaceutical products, including antibiotics and anesthesia drugs, to support military health care programs. The contract has a period of performance through...
- This is a delivery order award to Sagent Pharmaceuticals, Inc., a for-profit pharmaceutical manufacturer, by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh. The award has a potential value of $4,854,220.80 and is a firm fixed price contract for the delivery of various injectable pharmaceutical products, primarily antibiotics and anesthesia medications, to support military health care programs. The award is not associated with a set-aside...
- This is a firm fixed-price delivery order awarded by the Centers for Disease Control and Prevention (CDC) to Sagent Pharmaceuticals, Inc., a specialty pharmaceutical manufacturer, for the provision of injectable pharmaceutical products under the SAGENT TASK ORDER 0001. The contract has a ceiling value of $200,985.60 and an ultimate completion date of September 27, 2016. Sagent Pharmaceuticals is a for-profit organization and a registered federal contractor, supplying critical medical supplies...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Sagent Pharmaceuticals, Inc., a specialty pharmaceutical manufacturer. The $423,014.40 firm fixed-price contract is to provide CIPROFLOXACIN HCL 400MG/200ML, IN 5% DEX, a critical antibiotic medication, to support military healthcare programs and other federal medical needs. The contract has a completion date of February 22, 2017. Sagent Pharmaceuticals is a prime contractor on two significant federal...
- This federal contract award, with a ceiling value of $19,728.62, is a delivery order issued under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen Drug Corp, a major pharmaceutical distributor, with the Defense Logistics Agency (DLA) Troop Support Medical. The IDC, valued at $999,999,999, provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific delivery order is for pharmaceutical...
- This federal contract award, valued at $27,215.60, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under the company's Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
- SPE2D021D0003Indefinite Delivery Contract
- SPE2D021D0003-SPE2D022F0106Delivery Order
This federal contract award, valued at $85,281.13, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Sagent Pharmaceuticals, Inc., a specialty and generic pharmaceutical manufacturer. The delivery order contract is for the provision of various injectable pharmaceutical products, including antibiotics, critical care medications, and anesthesia drugs to support military healthcare programs and other federal medical needs. The contract is not set aside and is a firm fixed-price delivery order that is part of Sagent Pharmaceuticals' larger $29.6 million single-award indefinite delivery/indefinite quantity (ID/IQ) contract with the DLA Troop Support Medical, valid through March 3, 2031. This master contract enables the rapid procurement and distribution of critical medicines to military treatment facilities worldwide. Sagent Pharmaceuticals also holds a $5.5 million Federal Supply Schedule contract with the Department of Veterans Affairs for drugs, pharmaceuticals, and hematology-related products, valid through April 30, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $85.3k | 3/1/22 |